万泰生物

603392.SH

Wind Industry: 医疗保健 > 医药生物 > 生物科技Ⅲ > 生物科技Ⅳ

公司成立于1991年，于2020年在沪市主板挂牌上市。公司始终秉持“以质量求生存、以科技创新求发展”的发展宗旨，致力于诊断试剂、疫苗以及医疗器械的研发、生产和销售，促进供需双方的精准对接，逐渐构建起市场需求与研发创新相互激励、有机联动的新型发展模式。公司主要业务分为体外诊断及疫苗两大类领域，通过产品的有机组合，为客户提供安全、有效的一体化健康解决方案。公司长期深耕体外诊断赛道，坚持自主研发为核心驱动力，依托高品质产品与专业化服务，为医学实验室提供切实有效的解决方案。诊断试剂方面布局全面、品类丰富，涵盖化学发光诊断试剂、酶联免疫诊断试剂、生化诊断试剂、胶体金诊断试剂、核酸诊断试剂、临床检验质控品及标准物质等。全系试剂可针对血清、血浆、尿液等多种人体样本开展检测，精准获取临床诊断信息与血样信息，为临床诊断提供坚实依据。仪器方面，公司已形成由高速全自动化学发光免疫分析仪Wan600、全自动生化分析仪Wan BC2800、WanTLA Prime及WanTLA Mini自动化流水线等构成的产品布局，并持续推进全实验室自动化、核酸检测及智慧实验室相关产品研发，满足不同层级医疗机构的检测需求。公司始终聚焦于高价值疫苗产品的研发创新与成果转化，构建了以HPV疫苗为核心的多元化产品布局。公司在生命健康领域率先进行战略布局，主要研发与生产基地设于北京市及福建省厦门市，坚持自主创新、坚持关键技术攻关，走产学研相结合道路，现已发展成为我国创新免疫诊断产品和创新疫苗研发的领先企业。

ESG Score Industry Ranking:
1 / 165 (生物科技Ⅲ)

ESG Rating Distribution(生物科技Ⅲ)

AAA

7.88%

24.24%

27.88%

BBB

26.06%

10.91%

1.21%

CCC

Trend of Rating

About Wind ESG Rating

Wind has developed a rigorous rating methodology based on the core connotations of ESG, aligning with international standards and frameworks, and incorporating the characteristics of Chinese companies, to assess the company's essential ESG performance, risk and its ability to operate sustainably.

Focusing on the ESG risks and opportunities of each industry, the companies are rated on a AAA-CCC scale relative to the performance of their industry peers. Wind ESG rating is updated annually or in response to major changes.

The Wind ESG Rating Issuer Communication Platform (esg.wind.com.cn) is now available. Rated companies can access their detailed rating information through this platform, and communicate with or provide feedback to the Wind ESG Rating team regarding specific rating components. For any additional questions, please feel free to send an email to GR.ESG@wind.com.cn.

ESG Score

ESG Score：8.86Updated on 2026-10-29

08.8610

Management & Practices Score：5.90Updated on 2026-10-28

05.907

Controversies Score：2.96Updated on 2026-10-29

02.963

ESG Score Comparison

Indicator	Company Score	Industry Average	Weight
Environmental	7.57	3.67	12.53%
Social	8.54	4.54	57.57%
Governance	8.58	5.78	29.91%

Wind ESG Rating Framework

Building on the foundation of domestic and international ESG policies and standards, our proprietary ESG rating framework considers the development of Chinese capital market and integrates the characteristics of the Chinese companies in various industries. The Wind ESG Rating framework is composed of management & practice and controversies assessment, including:

500+ management & practices indicators, covering E, S and G pillars, reflecting long-term ESG fundamental impacts
1,200+ risk labels, covering news, regulatory penalties and lawsuits, reflecting impact of short-term risks

Management & practice score is the weighted summation of E, S and G pillar scores. The weights reflect both the relative impact of each issue within each industry and the negative or positive contribution of each industry to the environment and society relative to other industries.

Controversies score and ESG score are updated daily, E, S and G pillar scores and management & practice score are updated with underlying data, corresponding data are released on various channels, including Wind Financial Terminal.

Explore More

Wind ESG Rating Methodology.pdf1,198KB Wind ESG Ratings FAQs.pdf755KB

More Details

Peer Comparison(165 companies in the industry) ?

Ranking	Code	Security Name	ESG Rating	ESG Score	Controversies Score	Management & Practices Score	Environmental	Social	Governance
1	603392.SH	万泰生物	AA	8.86	2.96	5.90	7.57	8.54	8.58
2	002252.SZ	上海莱士	AA	8.68	2.99	5.69	7.75	8.12	8.29
3	1801.HK	信达生物	AA	8.62	3.00	5.62	7.78	8.03	8.12
4	300142.SZ	沃森生物	AA	8.42	2.94	5.48	5.48	8.14	8.21
5	2269.HK	药明生物	AA	8.28	3.00	5.28	8.45	7.47	7.29
6	1530.HK	三生制药	AA	8.26	2.99	5.26	7.56	7.43	7.68
7	920344.BJ	三元基因	AA	8.16	2.96	5.20	4.33	7.97	7.69
7	300122.SZ	智飞生物	AA	8.16	2.97	5.19	5.40	7.42	8.24
9	6660.HK	艾美疫苗	AA	8.12	3.00	5.12	6.39	7.37	7.57
10	6855.HK	亚盛医药	AA	8.11	2.99	5.12	7.21	7.73	6.59